U.S. Venture Partners (USVP), founded in 1981 and based in Menlo Park, California, is a venture capital firm that specializes in early-stage investments. The firm focuses on transformative ideas within the information technology and healthcare sectors, emphasizing innovation that drives economic growth and job creation. USVP's investment areas include enterprise software, IT security, consumer internet, mobile applications, e-commerce, healthcare, and IT-enabled healthcare services. The team at USVP comprises former entrepreneurs, technologists, corporate executives, financial professionals, and industry experts, all dedicated to supporting entrepreneurs in their journey to build impactful companies. The firm primarily targets businesses located on the West Coast of the United States, seeking opportunities in B2B, life sciences, oncology, cybersecurity, digital health, and cloud technology.
HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.
MicroTransponder
Series F in 2025
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.
Shoulder Innovations
Series E in 2025
Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leverages this technology to create simple surgical instrumentation, which reduces operative time and cost. Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery.
Nervonik
Series A in 2025
Nervonik is a medical device company specializing in the development of an opioid-free peripheral nerve stimulation system. The company focuses on advancing its clinical research and achieving regulatory approvals for its innovative neuro-modulation device, which is designed for therapeutic applications. This miniaturized device employs sensing feedback to deliver closed-loop optimized therapy, allowing patients to receive targeted treatment for chronic disorders. Through its commitment to innovation, Nervonik aims to provide effective alternatives for pain management without reliance on opioids.
Delfina
Series A in 2025
Delfina is a company that specializes in developing a personalized prenatal care system aimed at ensuring the safety of mothers and infants during pregnancy. By leveraging data and machine learning, Delfina's platform creates individualized pregnancy care plans that assess patient risk through various metrics. This approach not only enhances interventional workflows but also improves provider efficiency, facilitating early intervention in prenatal care. Delfina's commitment to data-driven insights is paving the way for clinical innovation, ultimately striving to deliver equitable and cost-effective healthcare solutions for expectant families.
Quantifind
Venture Round in 2025
Quantifind, Inc. is a data science company that specializes in creating on-demand insights platforms aimed at enhancing marketing effectiveness and detecting financial crimes such as money laundering and fraud. Founded in 2008 by two Ph.D. graduates in atomic physics, the company offers several key products, including signum Analysis, which helps users assess performance drivers for brands and competitors; signum Voice, which focuses on revenue drivers; and signum Impact, which measures the effects of sponsorships on brand awareness and sales. Additionally, Quantifind's platform integrates internal financial institution data with public domain data to identify risks, thereby assisting financial crime analysts in minimizing false positive alerts and managing risk. The company serves various sectors, including automotive, consumer packaged goods, entertainment, financial services, pharmaceuticals, retail, and telecommunications, and has established a strategic partnership with Oracle Financial Services. Quantifind is headquartered in Menlo Park, California, with additional offices in Silicon Valley, New York, and Washington, D.C.
Stream Security
Series B in 2024
Stream Security provides real-time cloud threat and exposure detection solutions, helping SecOps teams manage security in cloud environments. The Stream Security platform empowers SecOps teams with unmatched visibility, enabling them to identify vulnerabilities and threats by comprehending the past, present, and future of their cloud infrastructure. The AI-powered platform assists in determining attack paths and blast radius across all cloud infrastructure components, helping to eliminate gaps, accelerate MTTR through streamlined investigations, reduce knowledge gaps, maximize team productivity, and mitigate burnout.
Okami Medical
Venture Round in 2024
Okami Medical, Inc. is a manufacturer of medical devices specializing in the occlusion of peripheral vessels, primarily through its innovative LOw-profile Braided Occluder (LOBO) system. This device provides interventional physicians with a single solution for occluding various arterial targets, eliminating the need for multiple embolic devices. The LOBO incorporates proprietary HDBRAID technology, which features a unique pore structure that effectively reduces blood flow and accelerates vessel closure. Founded in 2011 and headquartered in Aliso Viejo, California, Okami Medical was established to meet the evolving needs of patients and healthcare providers by developing versatile and intuitive devices that ensure rapid and reliable vessel occlusion under diverse conditions.
ShiraTronics
Series B in 2024
ShiraTronics, Inc. is a company that specializes in developing and commercializing neuromodulation therapies aimed at treating chronic migraines, a condition that significantly impacts the lives of millions worldwide. Founded in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics is focused on addressing unmet clinical needs in neurology. The company's innovative technologies offer new approaches to effectively alleviate the debilitating effects of migraine headaches, thereby striving to improve the quality of life for those affected by this disabling disorder.
Route 92
Series F in 2024
Route 92 Medical is a medical device company founded in 2015 and based in San Mateo, California. The company specializes in developing innovative solutions for stroke treatment, focusing on a stealthy catheter designed for acute ischemic stroke. Their technology includes a percutaneous catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery mechanism. These advancements aim to assist healthcare professionals in effectively treating stroke patients and enhancing their recovery outcomes.
Sepio
Series B in 2024
Sepio has developed an innovative asset risk management platform focused on protecting organizations from hardware-based attacks. Unlike traditional methods that monitor asset activity, Sepio's solution uses physical layer asset DNA profiling to provide actionable visibility and control over hardware assets. This platform enables security teams to gain comprehensive insight into their infrastructure, regardless of whether it includes IT, OT, or IoT components. With trafficless monitoring, the solution reports the actual assets present within 24 hours, along with associated risk factors, allowing for effective policy enforcement and mitigation of rogue devices. By enabling administrators to define granular usage rules and continuously monitor their hardware assets, Sepio enhances cybersecurity posture and helps organizations manage their assets efficiently and securely.
Sparrow Pharmaceuticals
Venture Round in 2024
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for disorders related to corticosteroid excess. Founded in 2013 by David A. Katz and based in Portland, Oregon, the company aims to provide better therapeutic options for patients suffering from hypercortisolism and autoimmune or inflammatory conditions. By utilizing unique insights into corticosteroid biology, Sparrow is advancing its lead product, SPI-62, an oral small molecule treatment that specifically targets the source of active intracellular corticosteroids in critical tissues. This approach is designed to alleviate the adverse effects of both naturally occurring corticosteroids, such as cortisol due to tumors, and the long-term use of corticosteroid medications like prednisone.
Carlsmed
Series C in 2024
Carlsmed is a medical technology company based in San Diego, California, specializing in spine surgery solutions. Founded in 2018, the company has developed the aprevo™ implant system, which is the first surgical implant designated as a breakthrough technology by the FDA. This innovative 3-D printed implant system offers personalized medicine benefits specifically for lumbar fusion surgery. Carlsmed employs machine learning technologies and analysis of prior outcomes data to enhance the treatment of complex adult spinal deformities, aiming to improve surgical outcomes and reduce healthcare costs associated with spine surgery. The company serves hospitals and surgeons nationwide, providing advanced solutions for adult spinal malalignment.
Cagent Vascular
Series C in 2024
Cagent Vascular, LLC is a medical device company based in Wayne, Pennsylvania, focused on developing innovative solutions for cardiovascular diseases. The company specializes in angioplasty balloons that utilize proprietary serration technology to enhance treatment outcomes. Its flagship product, the Serranator, features serrated metal strips embedded in a semi-compliant balloon, designed specifically for the treatment of atherosclerosis and conditions such as peripheral artery disease and chronic limb-threatening ischemia. By employing a minimally invasive approach, Cagent Vascular aims to improve vessel dilatation during cardiovascular interventions, ultimately enhancing patient care and quality of life. Founded in 2014, the company is dedicated to advancing intravascular technology in the medical field.
IONIX
Series A in 2024
IONIX specializes in attack surface management, offering a solution that identifies and monitors exploitable risks across a company's digital landscape and supply chain. Utilizing advanced machine learning, IONIX's platform discovers internet-facing assets and their connections, helping organizations to understand and prioritize critical vulnerabilities. The platform employs innovative detection techniques to uncover new assets and analyze their relationships, addressing the gap between traditional security measures and the tactics employed by modern attackers. Prominent companies such as Infosys, Warner Music Group, The Telegraph, and E.ON rely on IONIX for its comprehensive risk assessment and remediation tools, which empower them to proactively manage their security posture in an increasingly complex threat environment.
Zero Networks
Series B in 2023
Zero Networks Inc., founded in 2019 and based in Tel Aviv, Israel, specializes in cloud-based network security software. The company focuses on automating the development and enforcement of network access rules, allowing organizations to customize access for users and machines based on their communication patterns. Its technology eliminates the need for agents or manual policy configurations, providing a streamlined security solution. Additionally, Zero Networks includes a two-factor authentication mechanism that allows for secure connectivity even in unusual situations, ensuring that legitimate connections remain unaffected. By automating network access policies, Zero Networks aims to enhance security and prevent breaches, thereby safeguarding organizational operations.
Stensul
Series C in 2023
Stensul is an email generation platform designed to streamline the email creation process for enterprise marketers. By centralizing and pre-configuring the platform for each brand, Stensul eliminates the need for extensive collaboration with designers, developers, and quality assurance teams. This allows marketers to concentrate on crafting engaging content that drives results. The platform simplifies complex coding and design tasks, enabling marketing teams to produce mobile-responsive emails that adhere to brand and legal guidelines. With Stensul, businesses can efficiently build and send emails through their existing email service providers or marketing clouds, ultimately reducing production time and costs while enhancing communication effectiveness.
Route 92
Series F in 2023
Route 92 Medical is a medical device company founded in 2015 and based in San Mateo, California. The company specializes in developing innovative solutions for stroke treatment, focusing on a stealthy catheter designed for acute ischemic stroke. Their technology includes a percutaneous catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery mechanism. These advancements aim to assist healthcare professionals in effectively treating stroke patients and enhancing their recovery outcomes.
Luminopia
Series A in 2023
Luminopia is focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. The company is creating digital therapeutics that undergo rigorous evaluation for FDA approval while ensuring they are engaging for patients. In collaboration with Boston Children's Hospital, Luminopia is advancing its primary product, Luminopia One, which utilizes a binocular therapeutic approach to effectively address amblyopia. This development aims to enhance the capabilities of healthcare professionals in treating these critical vision disorders.
TrustLab
Series A in 2023
Trust Lab develops software for social media platforms that helps in detecting misinformation, hate speech, and harmful content.
Percepto
Series C in 2023
Percepto is a developer of autonomous drone technology for inspection and surveillance. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the first deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring), the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.
Surgical Safety Technologies
Series A in 2023
Surgical Safety Technologies specializes in providing data-driven artificial intelligence technology to hospitals, aimed at enhancing surgical safety. The company’s platform offers an objective assessment of both technical and non-technical skills of surgeons, utilizing academically validated frameworks. By delivering descriptive, predictive, and prescriptive insights, the platform supports data-driven clinical and operational decisions, ultimately improving surgical quality and patient safety in healthcare settings.
HeartFlow
Series F in 2023
HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.
Shoulder Innovations
Series D in 2023
Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leverages this technology to create simple surgical instrumentation, which reduces operative time and cost. Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery.
Quantifind
Venture Round in 2023
Quantifind, Inc. is a data science company that specializes in creating on-demand insights platforms aimed at enhancing marketing effectiveness and detecting financial crimes such as money laundering and fraud. Founded in 2008 by two Ph.D. graduates in atomic physics, the company offers several key products, including signum Analysis, which helps users assess performance drivers for brands and competitors; signum Voice, which focuses on revenue drivers; and signum Impact, which measures the effects of sponsorships on brand awareness and sales. Additionally, Quantifind's platform integrates internal financial institution data with public domain data to identify risks, thereby assisting financial crime analysts in minimizing false positive alerts and managing risk. The company serves various sectors, including automotive, consumer packaged goods, entertainment, financial services, pharmaceuticals, retail, and telecommunications, and has established a strategic partnership with Oracle Financial Services. Quantifind is headquartered in Menlo Park, California, with additional offices in Silicon Valley, New York, and Washington, D.C.
HealthJoy
Series D in 2022
HealthJoy, LLC operates an online healthcare decision platform that aims to reduce out-of-pocket expenses for consumers by enabling better healthcare decisions. Founded in 2014 and based in Chicago, the company focuses on enhancing the benefits experience for employees while assisting organizations in managing costs. Through personalized guidance and AI-driven technology, HealthJoy provides employees with a digital benefits wallet that integrates their existing benefits, ensuring they remain informed about their options. The platform offers on-demand access to online medical consultations, healthcare concierges, and prescription savings, empowering users to make educated choices about their healthcare. By simplifying the healthcare experience and offering insights into cost-effective care options, HealthJoy helps employees improve their satisfaction and reduces the burden on human resources.
Sepio
Series B in 2022
Sepio has developed an innovative asset risk management platform focused on protecting organizations from hardware-based attacks. Unlike traditional methods that monitor asset activity, Sepio's solution uses physical layer asset DNA profiling to provide actionable visibility and control over hardware assets. This platform enables security teams to gain comprehensive insight into their infrastructure, regardless of whether it includes IT, OT, or IoT components. With trafficless monitoring, the solution reports the actual assets present within 24 hours, along with associated risk factors, allowing for effective policy enforcement and mitigation of rogue devices. By enabling administrators to define granular usage rules and continuously monitor their hardware assets, Sepio enhances cybersecurity posture and helps organizations manage their assets efficiently and securely.
SecuriThings
Series B in 2022
SecuriThings, Inc. specializes in providing comprehensive security solutions for Internet of Things (IoT) devices, leveraging big data and machine learning to detect cyber threats in real time. Founded in 2015 and headquartered in Tel Aviv, with an additional office in New York, the company offers a range of services including physical security through video surveillance, access control, and intrusion detection, as well as IoT networks for smart cities and building automation. Its Horizon platform enhances operational efficiency and cybersecurity, delivering automation, analytics, and actionable alerts to ensure the secure operation of IoT devices. Trusted by Fortune 100 companies, SecuriThings has successfully implemented its solutions in large enterprises such as airports, universities, and hospitals. The company collaborates with system integrators and device manufacturers to provide robust insights and reliability in IoT security management.
Oliver Space
Series B in 2022
Oliver Space is a home furnishing company founded in 2018 in San Francisco, California, by Chan Park. The company specializes in providing a wide range of furniture and home decor products, including sofas, rugs, pillows, and plants, through an online platform. Oliver Space offers customers flexible payment options, allowing them to either rent or purchase items on a monthly subscription basis. This model enables individuals to create aesthetically pleasing living spaces without the burden of high upfront costs. Additionally, customers can enjoy a trial period before committing to a purchase, with the option of 0% interest financing, making home decoration both easy and affordable.
TaskHuman
Series B in 2022
TaskHuman, Inc. operates an online platform that facilitates video coaching aimed at enhancing personal wellness. Founded in 2017 and based in Palo Alto, California, the platform connects users with a diverse network of coaches, including athletic trainers, life coaches, nutrition experts, yoga instructors, and specialists across various wellness domains. TaskHuman allows individuals to engage in real-time, one-on-one interactive sessions through video calls, addressing over 1,000 aspects of well-being, such as physical fitness, mental health, spiritual growth, and career development. The company aims to make self-care and personal wellness accessible and affordable, empowering users to improve their health and lifestyle through personalized coaching.
MicroTransponder
Series E in 2022
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.
Nfinite
Series B in 2022
Nfinite is a company that specializes in developing a cloud-based platform utilizing AI and 3D technology to enhance product visualization for brands and retailers. Founded in 2017 and based in the US and France, Nfinite offers a comprehensive suite of services that includes AI training and fine-tuning, leveraging high-quality synthetic data to customize AI models for specific industry needs. Its proprietary computer-generated imagery technology enables the creation of diverse visual content through virtual shooting, allowing retailers to replace traditional photographic images for online displays and catalogs. By providing limitless product visual experiences, Nfinite aims to improve sales and streamline the merchandising process for various sectors.
Carlsmed
Series B in 2022
Carlsmed is a medical technology company based in San Diego, California, specializing in spine surgery solutions. Founded in 2018, the company has developed the aprevo™ implant system, which is the first surgical implant designated as a breakthrough technology by the FDA. This innovative 3-D printed implant system offers personalized medicine benefits specifically for lumbar fusion surgery. Carlsmed employs machine learning technologies and analysis of prior outcomes data to enhance the treatment of complex adult spinal deformities, aiming to improve surgical outcomes and reduce healthcare costs associated with spine surgery. The company serves hospitals and surgeons nationwide, providing advanced solutions for adult spinal malalignment.
IONIX
Series A in 2022
IONIX specializes in attack surface management, offering a solution that identifies and monitors exploitable risks across a company's digital landscape and supply chain. Utilizing advanced machine learning, IONIX's platform discovers internet-facing assets and their connections, helping organizations to understand and prioritize critical vulnerabilities. The platform employs innovative detection techniques to uncover new assets and analyze their relationships, addressing the gap between traditional security measures and the tactics employed by modern attackers. Prominent companies such as Infosys, Warner Music Group, The Telegraph, and E.ON rely on IONIX for its comprehensive risk assessment and remediation tools, which empower them to proactively manage their security posture in an increasingly complex threat environment.
Kryptowire
Venture Round in 2022
Kryptowire was jumpstarted by the Defense Advanced Research Projects Agency (DARPA) and the Department of Homeland Security (DHS S&T), and has been vetted by the US military, law enforcement, and intelligence agencies. Kryptowire provides mobile application security analysis tools, antiâ€piracy technologies, mobile app marketplace security analytics, and Enterprise Mobility Management (EMM) solutions. Kryptowire was founded in 2011, is based in Fairfax, Virginia, and has a customer base ranging from government agencies to national cable TV companies.
Nfinite
Series A in 2022
Nfinite is a company that specializes in developing a cloud-based platform utilizing AI and 3D technology to enhance product visualization for brands and retailers. Founded in 2017 and based in the US and France, Nfinite offers a comprehensive suite of services that includes AI training and fine-tuning, leveraging high-quality synthetic data to customize AI models for specific industry needs. Its proprietary computer-generated imagery technology enables the creation of diverse visual content through virtual shooting, allowing retailers to replace traditional photographic images for online displays and catalogs. By providing limitless product visual experiences, Nfinite aims to improve sales and streamline the merchandising process for various sectors.
Hunters
Series C in 2022
Hunters is a cybersecurity company that specializes in developing an artificial intelligence-based platform for detecting and responding to cyber threats. Founded in 2018 and headquartered in Tel Aviv, Israel, the company offers its solution, Hunters.AI, which autonomously identifies cyberattacks that may evade traditional security measures across various IT environments, including cloud and network systems. Hunters.AI integrates diverse security telemetry and intelligence, enriching threat signals with detailed tactics, techniques, and procedures to enhance detection capabilities. By utilizing machine learning and cloud-based analytics, the platform correlates threat patterns and generates high-fidelity attack narratives, enabling cybersecurity teams to respond swiftly and effectively to potential breaches.
Qnovo
Series C in 2022
Qnovo is a company focused on advancing lithium-ion battery technology through its innovative battery management software and predictive analytics. Established in 2010 and headquartered in Milpitas, California, Qnovo aims to enhance the performance and safety of electric vehicles, energy storage systems, and consumer devices. The company has developed a unique approach to battery charging that involves real-time measurement of battery health, allowing for faster charging and extended battery lifespan. With a portfolio of over 50 patents, Qnovo collaborates with leading automotive manufacturers and has its technology integrated into over 150 million smartphones globally. Its investors include prominent firms in the technology and climate sectors.
Route 92
Series E in 2021
Route 92 Medical is a medical device company founded in 2015 and based in San Mateo, California. The company specializes in developing innovative solutions for stroke treatment, focusing on a stealthy catheter designed for acute ischemic stroke. Their technology includes a percutaneous catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery mechanism. These advancements aim to assist healthcare professionals in effectively treating stroke patients and enhancing their recovery outcomes.
TaskHuman
Series A in 2021
TaskHuman, Inc. operates an online platform that facilitates video coaching aimed at enhancing personal wellness. Founded in 2017 and based in Palo Alto, California, the platform connects users with a diverse network of coaches, including athletic trainers, life coaches, nutrition experts, yoga instructors, and specialists across various wellness domains. TaskHuman allows individuals to engage in real-time, one-on-one interactive sessions through video calls, addressing over 1,000 aspects of well-being, such as physical fitness, mental health, spiritual growth, and career development. The company aims to make self-care and personal wellness accessible and affordable, empowering users to improve their health and lifestyle through personalized coaching.
Luma Health
Series C in 2021
Luma Health Inc. is a San Francisco-based company that specializes in developing a patient engagement platform aimed at enhancing the connection between healthcare providers and patients. Founded in 2015, the platform facilitates smart scheduling and referral management while offering features such as appointment reminders, mobile patient intake, and care pathways. It enables healthcare systems and clinics to keep their schedules full and supports patient adherence to care plans. Additionally, Luma Health provides tools for patient communication and analytics, ensuring that healthcare providers can deliver continuous care and improve treatment outcomes. The company emphasizes a modern, mobile-first approach to patient engagement.
Effector Therapeutics
Post in 2021
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.
Hunters
Series B in 2021
Hunters is a cybersecurity company that specializes in developing an artificial intelligence-based platform for detecting and responding to cyber threats. Founded in 2018 and headquartered in Tel Aviv, Israel, the company offers its solution, Hunters.AI, which autonomously identifies cyberattacks that may evade traditional security measures across various IT environments, including cloud and network systems. Hunters.AI integrates diverse security telemetry and intelligence, enriching threat signals with detailed tactics, techniques, and procedures to enhance detection capabilities. By utilizing machine learning and cloud-based analytics, the platform correlates threat patterns and generates high-fidelity attack narratives, enabling cybersecurity teams to respond swiftly and effectively to potential breaches.
Carrot Fertility
Series C in 2021
Carrot Fertility, Inc. specializes in providing comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey on a global scale. The company's offerings include services such as egg freezing, in vitro fertilization, adoption, donor and gestational carrier services, as well as a premium pharmacy experience for fertility medications through Carrot Rx. Additionally, Carrot Pregnancy provides virtual access to experts and on-demand doctor-approved content, while the Carrot Card allows employees to use a flexible debit card for their fertility-related expenses. By customizing these benefits, Carrot Fertility aims to deliver financial, medical, and emotional support for individuals pursuing parenthood. Founded in 2015 and headquartered in San Francisco, California, the company also maintains offices in Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.
Ribon Therapeutics
Series C in 2021
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.
Standard Bariatrics
Series B in 2021
Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in developing surgical instruments designed specifically for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products, the Standard Clamp, enables surgeons to standardize their techniques, thereby reducing variation and improving efficiency during procedures. The company’s tools are intended to be used alongside general-use endoscopic staplers with reloadable cartridges, which helps to minimize the number of cartridges required for each surgery. This innovation not only lowers costs for healthcare providers but also assists in creating consistent surgical outcomes.
Oliver Space
Series A in 2021
Oliver Space is a home furnishing company founded in 2018 in San Francisco, California, by Chan Park. The company specializes in providing a wide range of furniture and home decor products, including sofas, rugs, pillows, and plants, through an online platform. Oliver Space offers customers flexible payment options, allowing them to either rent or purchase items on a monthly subscription basis. This model enables individuals to create aesthetically pleasing living spaces without the burden of high upfront costs. Additionally, customers can enjoy a trial period before committing to a purchase, with the option of 0% interest financing, making home decoration both easy and affordable.
Sparrow Pharmaceuticals
Series A in 2021
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for disorders related to corticosteroid excess. Founded in 2013 by David A. Katz and based in Portland, Oregon, the company aims to provide better therapeutic options for patients suffering from hypercortisolism and autoimmune or inflammatory conditions. By utilizing unique insights into corticosteroid biology, Sparrow is advancing its lead product, SPI-62, an oral small molecule treatment that specifically targets the source of active intracellular corticosteroids in critical tissues. This approach is designed to alleviate the adverse effects of both naturally occurring corticosteroids, such as cortisol due to tumors, and the long-term use of corticosteroid medications like prednisone.
Informed
Series A in 2021
Informed, Inc. is a technology company based in San Francisco, California, established in 2016. It operates a platform designed to facilitate the connection between buyers and sellers of pre-owned cars while also providing services that enhance the digital transformation of banks. The company offers a robotic process automation solution that performs essential verification tasks, including income, identity, residence, and insurance verifications. This automation helps banks minimize manual costs related to document reviews, mitigate fraud, reduce bias, and decrease errors during loan origination and account opening processes. Additionally, Informed's consumer auto financing platform features a digital assistant that gathers necessary documents from borrowers and employs machine learning and optical character recognition to streamline and automate the loan origination process for auto lenders.
AirEye
Series A in 2021
AirEye specializes in wireless security solutions aimed at protecting organizational networks from airborne attacks that exploit wireless communications such as Wi-Fi, cellular, 5G, and Bluetooth. Its flagship product, AirEye Dome, provides comprehensive monitoring and real-time protection against unauthorized network access, data leaks, and other security threats. The platform detects and blocks violations automatically, integrating seamlessly with existing network security infrastructures without requiring major architectural changes. By offering complete visibility and control over wireless activity, including employee hotspots and dual-connected devices, AirEye enables organizations to safeguard their IT and operational technology assets effectively. The solution is utilized across various sectors, including finance, healthcare, manufacturing, and aerospace, ensuring robust security against advanced persistent threats.
Territory Foods
Series B in 2021
Territory Foods is a chef-prepared meal delivery service that creates nutritionist-approved menus tailored to support various dietary preferences and regional market tastes. Its fresh, healthy, ready-to-eat meals are designed by in-house culinary professionals and nutrition experts, prepared by a dedicated team of chefs, and powered by a proprietary algorithm that informs personalized menu variety at scale. Its boredom-proof rotating menus feature a wide variety of freshly-made artisan meals per week that are responsibly sourced, always free of refined sugars, and made without ingredients that contain gluten and dairy. Menus can be customized to meet dietary templates such as Vegan, Vegetarian, Whole30, and Keto, taking the guesswork out of navigating and committing to healthy eating. Territory Foods launched in 2011 and is headquartered in Arlington, VA.
Dapper Labs
Series C in 2021
Dapper Labs Inc., founded in 2018 and based in Vancouver, Canada, specializes in the development of blockchain-based gaming and collectible platforms. The company is well-known for its flagship product, NBA Top Shot, which utilizes blockchain technology to create non-fungible tokens (NFTs) that engage fans and enhance their connection to their favorite sports brands. Dapper Labs aims to empower consumers by providing them with opportunities to participate in digital ecosystems, allowing them to track ownership securely and become creators within these communities. Through its innovative approach, the company fosters engaging experiences and builds vibrant communities centered around digital collectibles and entertainment.
Dapper Labs
Venture Round in 2021
Dapper Labs Inc., founded in 2018 and based in Vancouver, Canada, specializes in the development of blockchain-based gaming and collectible platforms. The company is well-known for its flagship product, NBA Top Shot, which utilizes blockchain technology to create non-fungible tokens (NFTs) that engage fans and enhance their connection to their favorite sports brands. Dapper Labs aims to empower consumers by providing them with opportunities to participate in digital ecosystems, allowing them to track ownership securely and become creators within these communities. Through its innovative approach, the company fosters engaging experiences and builds vibrant communities centered around digital collectibles and entertainment.
Act-On Software
Venture Round in 2021
Act-On Software, Inc. is a developer of a cloud-based marketing automation platform tailored for small and mid-sized businesses. The platform enables marketers to create and manage various marketing campaigns, including email marketing, website lead generation, social media marketing, and account-based marketing. Act-On's solutions help organizations attract prospects, convert leads, and measure campaign effectiveness while enhancing customer engagement and brand awareness. Additionally, the company offers professional consulting, support, and training services to optimize the use of its platform. Act-On serves diverse industries such as banking, insurance, manufacturing, technology, and agencies. Founded in 2006 and headquartered in Portland, Oregon, Act-On also has locations in Scottsdale, Arizona, and Reading, United Kingdom.
Neuros Medical
Series B in 2021
Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.
Carlsmed
Series A in 2020
Carlsmed is a medical technology company based in San Diego, California, specializing in spine surgery solutions. Founded in 2018, the company has developed the aprevo™ implant system, which is the first surgical implant designated as a breakthrough technology by the FDA. This innovative 3-D printed implant system offers personalized medicine benefits specifically for lumbar fusion surgery. Carlsmed employs machine learning technologies and analysis of prior outcomes data to enhance the treatment of complex adult spinal deformities, aiming to improve surgical outcomes and reduce healthcare costs associated with spine surgery. The company serves hospitals and surgeons nationwide, providing advanced solutions for adult spinal malalignment.
Edgewise Therapeutics
Series C in 2020
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.
Percepto
Series B in 2020
Percepto is a developer of autonomous drone technology for inspection and surveillance. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the first deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring), the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.
Shoulder Innovations
Venture Round in 2020
Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leverages this technology to create simple surgical instrumentation, which reduces operative time and cost. Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery.
Stensul
Series B in 2020
Stensul is an email generation platform designed to streamline the email creation process for enterprise marketers. By centralizing and pre-configuring the platform for each brand, Stensul eliminates the need for extensive collaboration with designers, developers, and quality assurance teams. This allows marketers to concentrate on crafting engaging content that drives results. The platform simplifies complex coding and design tasks, enabling marketing teams to produce mobile-responsive emails that adhere to brand and legal guidelines. With Stensul, businesses can efficiently build and send emails through their existing email service providers or marketing clouds, ultimately reducing production time and costs while enhancing communication effectiveness.
Silverback Therapeutics
Series C in 2020
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.
Medigate by Claroty
Series B in 2020
Medigate by Claroty is a developer of a medical device security platform that safeguards healthcare provider networks from cyber threats. Founded in 2017, the company is headquartered in New York City and focuses on protecting all connected medical devices within these networks. Its platform utilizes deep packet inspection to decode proprietary healthcare IoT protocols, providing visibility and security for IoT and medical devices. By offering threat detection and attack prevention services, Medigate enhances the safety and privacy of hospital environments, allowing for the secure deployment of both existing and new medical devices.
Carrot Fertility
Series B in 2020
Carrot Fertility, Inc. specializes in providing comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey on a global scale. The company's offerings include services such as egg freezing, in vitro fertilization, adoption, donor and gestational carrier services, as well as a premium pharmacy experience for fertility medications through Carrot Rx. Additionally, Carrot Pregnancy provides virtual access to experts and on-demand doctor-approved content, while the Carrot Card allows employees to use a flexible debit card for their fertility-related expenses. By customizing these benefits, Carrot Fertility aims to deliver financial, medical, and emotional support for individuals pursuing parenthood. Founded in 2015 and headquartered in San Francisco, California, the company also maintains offices in Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.
Hunters
Series A in 2020
Hunters is a cybersecurity company that specializes in developing an artificial intelligence-based platform for detecting and responding to cyber threats. Founded in 2018 and headquartered in Tel Aviv, Israel, the company offers its solution, Hunters.AI, which autonomously identifies cyberattacks that may evade traditional security measures across various IT environments, including cloud and network systems. Hunters.AI integrates diverse security telemetry and intelligence, enriching threat signals with detailed tactics, techniques, and procedures to enhance detection capabilities. By utilizing machine learning and cloud-based analytics, the platform correlates threat patterns and generates high-fidelity attack narratives, enabling cybersecurity teams to respond swiftly and effectively to potential breaches.
Okami Medical
Series D in 2020
Okami Medical, Inc. is a manufacturer of medical devices specializing in the occlusion of peripheral vessels, primarily through its innovative LOw-profile Braided Occluder (LOBO) system. This device provides interventional physicians with a single solution for occluding various arterial targets, eliminating the need for multiple embolic devices. The LOBO incorporates proprietary HDBRAID technology, which features a unique pore structure that effectively reduces blood flow and accelerates vessel closure. Founded in 2011 and headquartered in Aliso Viejo, California, Okami Medical was established to meet the evolving needs of patients and healthcare providers by developing versatile and intuitive devices that ensure rapid and reliable vessel occlusion under diverse conditions.
Zerto
Series F in 2020
Zerto Ltd. specializes in disaster recovery and business continuity software for virtualized data centers and cloud environments. Founded in 2009 and headquartered in Boston, Massachusetts, the company offers the Zerto Cloud Continuity Platform, which includes its flagship product, Zerto Virtual Replication. This software enables organizations to protect, recover, and migrate applications across public, private, and hybrid clouds. Zerto's solutions are designed to simplify the complexities associated with modernization and cloud adoption, making it easier for enterprises to maintain continuous operations. The company's products are utilized in various applications, including Oracle, SAP, and SQL server replication and recovery, serving industries such as healthcare, legal, and finance. Zerto operates globally, with offices in locations including Israel, Japan, the United Kingdom, India, Canada, Mexico, and Brazil.
Cato Networks
Series D in 2020
Cato Networks Ltd. is a provider of a cloud-based network Security-as-a-Service platform that integrates networking and security solutions for enterprises. Founded in 2015 and headquartered in Tel Aviv, Israel, with additional offices in locations such as California, the United Kingdom, Singapore, Hong Kong, and Australia, the company offers a secure global SD-WAN. Cato's platform connects various enterprise locations, personnel, and data while optimizing application access across all users and locations. Key features include WAN optimization, firewall protection, secure web gateways, and threat protection. Cato Networks enables organizations to reduce costs associated with MPLS, improve performance for global locations and cloud applications, and eliminate the need for branch appliances, all while providing secure internet access and integrating mobile users and cloud data centers into the network seamlessly.
Forager
Series A in 2020
Forager Group, Inc., based in Chicago, Illinois, specializes in cross-border freight brokerage and logistics services primarily for the automotive and aerospace industries. Founded in 2018, the company offers a range of truckload services, including standard, expedited, and cross-border options. Forager leverages advanced technology and extensive industry experience to address the challenges faced by cross-border shippers, providing modern transportation solutions that enhance service quality. Additionally, the company features a user-friendly web-based transportation management platform designed to streamline operations and facilitate the shipping process between the United States, Mexico, and Canada.
Arkose Labs
Series B in 2020
Arkose Labs, based in San Francisco, California, develops a cybersecurity platform aimed at preventing online fraud and abuse for various industries, including online marketplaces, travel, banking, social media, ticketing, and gaming. Established in 2015, the company offers solutions to combat issues such as account takeover, fake account abuse, scraping, spam, and gift card fraud. Arkose Labs employs an AI-powered system that combines risk assessments with dynamic threat responses, effectively mitigating attacks while enhancing legitimate user experiences. The platform is recognized for its effectiveness, having received accolades for customer satisfaction and market presence. Additionally, it provides unique warranties against credential stuffing and SMS toll fraud, further demonstrating its commitment to protecting businesses from cybercrime. With a significant portion of its clientele being Fortune 500 companies, Arkose Labs operates offices in major locations, including Brisbane, Australia, and has established a strong reputation in the cybersecurity landscape.
Silverback Therapeutics
Series B in 2020
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.
HealthJoy
Series C in 2020
HealthJoy, LLC operates an online healthcare decision platform that aims to reduce out-of-pocket expenses for consumers by enabling better healthcare decisions. Founded in 2014 and based in Chicago, the company focuses on enhancing the benefits experience for employees while assisting organizations in managing costs. Through personalized guidance and AI-driven technology, HealthJoy provides employees with a digital benefits wallet that integrates their existing benefits, ensuring they remain informed about their options. The platform offers on-demand access to online medical consultations, healthcare concierges, and prescription savings, empowering users to make educated choices about their healthcare. By simplifying the healthcare experience and offering insights into cost-effective care options, HealthJoy helps employees improve their satisfaction and reduces the burden on human resources.
Epsagon
Series A in 2020
Epsagon’s SaaS platform allows Dev and Ops teams to troubleshoot less and fix issues faster by providing automated data correlation, payloads, and end-to-end observability within microservice environments. With our lightweight agent SDK, Epsagon provides automated instrumentation and tracing without gaps in coverage, giving you full visibility for containers, VMs, serverless, and more with no training, manual coding, tagging or maintenance required. Epsagon helps organizations and teams of all sizes to optimize costs through unlimited free monitoring and scalable pricing and increase engineering efficiency through reduced application downtime, faster shipping of features, and time saved in identifying and correcting issues.
ShiraTronics
Series A in 2019
ShiraTronics, Inc. is a company that specializes in developing and commercializing neuromodulation therapies aimed at treating chronic migraines, a condition that significantly impacts the lives of millions worldwide. Founded in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics is focused on addressing unmet clinical needs in neurology. The company's innovative technologies offer new approaches to effectively alleviate the debilitating effects of migraine headaches, thereby striving to improve the quality of life for those affected by this disabling disorder.
Kenna Security
Series D in 2019
Kenna Security, Inc. is a technology company that specializes in vulnerability management and risk intelligence solutions. Founded in 2009 and headquartered in San Francisco, with an additional office in Chicago, Kenna offers a platform that helps organizations prioritize vulnerabilities, assess risks, and automate their analysis. This platform leverages Cyber Risk Context Technology to measure and predict cyber risks, enabling security teams to focus on the most critical issues. Kenna serves a diverse range of sectors, including media, healthcare, telecommunications, financial services, and transportation, both in the United States and internationally. With a customer base that includes many Fortune 100 companies, Kenna's solutions facilitate cross-functional collaboration to proactively address cyber threats and enhance overall security efficacy.
Primary
Series C in 2019
Primary makes clothes for kids and builds a better experience for busy parents to shop for them. It aims to be the most inclusive kid's clothing brand, offering high-quality essentials at affordable prices. Rather than chasing the trend, Primary offers thoughtfully designed clothing without logos, slogans, or sequins. They take a gender-neutral approach, with a broad range of colors available for babies and kids 0-12, without prescribing what is for girls or boys. It was founded in 2015 and is headquartered in New York, New York.
Edgewise Therapeutics
Series B in 2019
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.
Luma Health
Series B in 2019
Luma Health Inc. is a San Francisco-based company that specializes in developing a patient engagement platform aimed at enhancing the connection between healthcare providers and patients. Founded in 2015, the platform facilitates smart scheduling and referral management while offering features such as appointment reminders, mobile patient intake, and care pathways. It enables healthcare systems and clinics to keep their schedules full and supports patient adherence to care plans. Additionally, Luma Health provides tools for patient communication and analytics, ensuring that healthcare providers can deliver continuous care and improve treatment outcomes. The company emphasizes a modern, mobile-first approach to patient engagement.
Entelo
Venture Round in 2019
Entelo is a recruitment platform that leverages data science and machine learning to assist companies in identifying and acquiring technical talent. Its SaaS-based solution automates the ranking and screening of inbound applicants, enhancing key recruitment metrics such as quality of hire, time to hire, and cost per hire. Trusted by over 600 customers across various industries, Entelo provides talent acquisition teams with actionable insights, improved candidate engagement, and increased productivity. Notable companies utilizing Entelo's services include Capital One, Cisco, Facebook, and Netflix.
Rimeto
Series A in 2019
Rimeto LLC, founded in 2016 and based in San Francisco, California, provides software solutions that enhance workplace collaboration through detailed employee directories and profiles. As a subsidiary of Slack Technologies, Rimeto specializes in integrating data from various enterprise systems to create a people-centric platform that simplifies access to information within organizations. By leveraging both public and proprietary data, Rimeto enables clients to build customized directories that facilitate project tracking and improve communication among teams. The company's mission is to empower employees by making information easily accessible and actionable, ultimately fostering a more connected and collaborative work environment.
Human Interest
Series B in 2019
Human Interest is a 401(k) provider that simplifies retirement savings for small and medium-sized businesses. Founded in 2015 in San Francisco by Paul Sawaya and Roger Lee, the company developed an end-to-end technology platform that addresses administrative and compliance challenges associated with retirement plans. This platform automatically creates employee accounts and syncs deductions with payroll providers, ensuring a streamlined process. In addition to facilitating employee retirement accounts, Human Interest offers personalized investment advice, enabling businesses to provide their employees with effective financial security solutions. The company has successfully assisted thousands of businesses across the United States in establishing accessible and affordable retirement plans.
Cleave Therapeutics
Series C in 2019
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.
Omada
Series D in 2019
Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.
Dstillery
Series D in 2019
Dstillery, Inc. is a digital intelligence platform that specializes in providing marketing solutions for brands and media partners. Founded in 2008 and based in New York City, the company offers a range of services aimed at enhancing brand awareness, consideration, and customer retention. Dstillery employs artificial intelligence to analyze consumer data, enabling brands to optimize their advertising strategies across mobile, desktop, and video channels. One of its notable products, ID-free®, offers a privacy-safe approach to behavioral targeting, ensuring comprehensive audience reach. The platform also features Dscover Maps, a geospatial insights tool that helps clients understand market composition based on geography. Dstillery's ongoing innovation is reflected in its numerous patents for advanced AI technology, which supports its mission to empower brands and agencies in executing high-performing programmatic advertising campaigns.
Percepto
Series A in 2019
Percepto is a developer of autonomous drone technology for inspection and surveillance. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the first deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring), the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.
Happy Returns
Venture Round in 2019
Happy Returns, Inc. is a company that specializes in providing in-person return solutions for online shoppers. Founded in 2015 and headquartered in Santa Monica, California, it operates a network of Return Bars where customers can return items in person and receive immediate refunds. The company handles the logistics of shipping returned items back to e-commerce retailers, thereby streamlining the return process for both consumers and businesses. By integrating technology and service, Happy Returns aims to offer a seamless return experience that meets the needs of shoppers while also providing retailers with cost-effective logistics solutions.
HealthJoy
Series B in 2019
HealthJoy, LLC operates an online healthcare decision platform that aims to reduce out-of-pocket expenses for consumers by enabling better healthcare decisions. Founded in 2014 and based in Chicago, the company focuses on enhancing the benefits experience for employees while assisting organizations in managing costs. Through personalized guidance and AI-driven technology, HealthJoy provides employees with a digital benefits wallet that integrates their existing benefits, ensuring they remain informed about their options. The platform offers on-demand access to online medical consultations, healthcare concierges, and prescription savings, empowering users to make educated choices about their healthcare. By simplifying the healthcare experience and offering insights into cost-effective care options, HealthJoy helps employees improve their satisfaction and reduces the burden on human resources.
Nuvaira
Series E in 2019
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.
Medigate by Claroty
Series A in 2019
Medigate by Claroty is a developer of a medical device security platform that safeguards healthcare provider networks from cyber threats. Founded in 2017, the company is headquartered in New York City and focuses on protecting all connected medical devices within these networks. Its platform utilizes deep packet inspection to decode proprietary healthcare IoT protocols, providing visibility and security for IoT and medical devices. By offering threat detection and attack prevention services, Medigate enhances the safety and privacy of hospital environments, allowing for the secure deployment of both existing and new medical devices.
Cato Networks
Series C in 2019
Cato Networks Ltd. is a provider of a cloud-based network Security-as-a-Service platform that integrates networking and security solutions for enterprises. Founded in 2015 and headquartered in Tel Aviv, Israel, with additional offices in locations such as California, the United Kingdom, Singapore, Hong Kong, and Australia, the company offers a secure global SD-WAN. Cato's platform connects various enterprise locations, personnel, and data while optimizing application access across all users and locations. Key features include WAN optimization, firewall protection, secure web gateways, and threat protection. Cato Networks enables organizations to reduce costs associated with MPLS, improve performance for global locations and cloud applications, and eliminate the need for branch appliances, all while providing secure internet access and integrating mobile users and cloud data centers into the network seamlessly.
HighLife
Series B in 2019
HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating patients with mitral valve regurgitation. Co-founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve that can be implanted in a beating heart while preserving the native valve structure and surrounding anatomy. The innovative system allows for delivery through a transseptal passage via the femoral vein, enabling a reversible procedure that minimizes patient trauma during complex heart surgeries. HighLife's focus is on ensuring ease and safety of use, contributing to improved treatment outcomes for patients. The company's technology is currently undergoing clinical evaluation.
Ribon Therapeutics
Series B in 2019
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.
NeoChord
Series D in 2018
NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, that focuses on developing innovative devices for the treatment of degenerative mitral valve disease (DMR). Founded in 2007, the company has created the NeoChord Artificial Chordae Delivery System, a disposable device designed for minimally invasive mitral valve repair. This system allows surgeons to replace damaged chordae through a small incision of 2 to 3 inches between the ribs, enabling the procedure to be performed on a beating heart. This approach contrasts sharply with traditional methods, which typically involve larger incisions and stopping the heart, thus reducing recovery time and associated complications. NeoChord's technology aims to improve surgical outcomes for patients suffering from severe mitral regurgitation, which can lead to serious conditions such as atrial fibrillation and congestive heart failure.
ZypMedia
Series C in 2018
ZypMedia, Inc., also known as ZypTV, operates a demand-side platform that connects advertisers with audiences on streaming television. Founded in 2013 and headquartered in San Francisco, the company has expanded to include offices in New York City, New Delhi, and Saint Petersburg. ZypMedia offers products like ZypTV Enterprise and ZypTV Self-Serve, tailored for local streaming TV advertising. The platform is designed for local media companies, media buying agencies, and brands seeking to effectively target local audiences at scale. By integrating machine learning with human expertise, ZypMedia provides tools that facilitate the transition between traditional and digital advertising, enabling clients to enhance their offerings and increase revenue in a rapidly evolving media landscape.
Arkose Labs
Series A in 2018
Arkose Labs, based in San Francisco, California, develops a cybersecurity platform aimed at preventing online fraud and abuse for various industries, including online marketplaces, travel, banking, social media, ticketing, and gaming. Established in 2015, the company offers solutions to combat issues such as account takeover, fake account abuse, scraping, spam, and gift card fraud. Arkose Labs employs an AI-powered system that combines risk assessments with dynamic threat responses, effectively mitigating attacks while enhancing legitimate user experiences. The platform is recognized for its effectiveness, having received accolades for customer satisfaction and market presence. Additionally, it provides unique warranties against credential stuffing and SMS toll fraud, further demonstrating its commitment to protecting businesses from cybercrime. With a significant portion of its clientele being Fortune 500 companies, Arkose Labs operates offices in major locations, including Brisbane, Australia, and has established a strong reputation in the cybersecurity landscape.
Raken
Series A in 2018
Raken provides mobile-first technology to streamline field workflows for the construction industry. Raken's digital toolbox connects the field to the office with daily reports, time cards, toolbox talks, photo management, production tracking and more. Swinerton Renewable Energy, John W. Danforth, Broadway Mechanical and thousands of other top general contractor and subcontractor firms use Raken for their field reporting needs. To find out more, visit www.rakenapp.com.
Luma Health
Series A in 2018
Luma Health Inc. is a San Francisco-based company that specializes in developing a patient engagement platform aimed at enhancing the connection between healthcare providers and patients. Founded in 2015, the platform facilitates smart scheduling and referral management while offering features such as appointment reminders, mobile patient intake, and care pathways. It enables healthcare systems and clinics to keep their schedules full and supports patient adherence to care plans. Additionally, Luma Health provides tools for patient communication and analytics, ensuring that healthcare providers can deliver continuous care and improve treatment outcomes. The company emphasizes a modern, mobile-first approach to patient engagement.
Inari Medical
Series C in 2018
Inari Medical, Inc. is a commercial-stage medical device company headquartered in Irvine, California, that specializes in developing innovative products for patients with venous diseases. Founded in 2011, the company focuses on treating venous thromboembolism through its advanced catheter-based mechanical thrombectomy devices. The ClotTriever system is designed for the safe and effective removal of large blood clots from peripheral blood vessels, specifically targeting deep vein thrombosis. The FlowTriever system addresses pulmonary embolism by removing clots from the pulmonary arteries. Both devices are FDA-cleared and aim to improve the quality of life for patients by eliminating the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States, while also engaging in international markets.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.